4-{2-[4-(4-chloro-3-trifluoromethylphenyl)-3,6-dihydro-2H-pyridin-1-yl]-2-oxoethyl}-1-(5-trifluoromethylpyridin-2-yl)piperazin-2-one | 1201225-06-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-{2-[4-(4-chloro-3-trifluoromethylphenyl)-3,6-dihydro-2H-pyridin-1-yl]-2-oxoethyl}-1-(5-trifluoromethylpyridin-2-yl)piperazin-2-one
• 英文别名: 4-[2-[4-[4-chloro-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridin-1-yl]-2-oxoethyl]-1-[5-(trifluoromethyl)pyridin-2-yl]piperazin-2-one
• CAS: 1201225-06-0
• 化学式: C₂₄H₂₁ClF₆N₄O₂
• 分子量: 546.9
• InChiKey: UYNCUTYQPHQBIH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  37
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  56.8
• 氢给体数：
  0
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  4-{2-[4-(4-chloro-3-trifluoromethylphenyl)-3,6-dihydro-2H-pyridin-1-yl]-2-oxoethyl}-1-(5-trifluoromethylpyridin-2-yl)piperazin-2-one 在 盐酸 作用下， 以 异丙醇 为溶剂， 生成 4-{2-[4-(4-chloro-3-trifluoromethylphenyl)-3,6-dihydro-2H-pyridin-1-yl]-2-oxoethyl}-1-(5-trifluoromethylpyridin-2-yl)piperazin-2-one hydrochloride
  参考文献：
  名称：

  DERIVATIVES OF 2-OXOALKYL-1-PIPERAZIN-2-ONE, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME

  摘要：

  本发明涉及具有通式（I）的4-{2-[苯基-3,6-二氢吡啶-1-基]-2-氧代烷基}-1-哌嗪-2-酮和4-{2-[苯基-2,5-二氢吡咯-1-基]-2-氧代烷基}-1-哌嗪-2-酮的衍生物，其中A、B、m、R3和n如本文所定义。该发明还涉及其制备方法和治疗用途。

  公开号：

  US20110144122A1
• 作为产物：
  描述：

  1-(4-chloro-3-trifluoromethyl phenyl)-3,6-dihydropyridine hydrochloride 在 potassium carbonate 、 三乙胺 、 sodium iodide 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.5h， 生成 4-{2-[4-(4-chloro-3-trifluoromethylphenyl)-3,6-dihydro-2H-pyridin-1-yl]-2-oxoethyl}-1-(5-trifluoromethylpyridin-2-yl)piperazin-2-one
  参考文献：
  名称：

  DERIVATIVES OF 2-OXOALKYL-1-PIPERAZIN-2-ONE, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME

  摘要：

  本发明涉及具有通式（I）的4-{2-[苯基-3,6-二氢吡啶-1-基]-2-氧代烷基}-1-哌嗪-2-酮和4-{2-[苯基-2,5-二氢吡咯-1-基]-2-氧代烷基}-1-哌嗪-2-酮的衍生物，其中A、B、m、R3和n如本文所定义。该发明还涉及其制备方法和治疗用途。

  公开号：

  US20110144122A1

文献信息

• DERIVES DE 2-OXO-ALKYL-1-PIPERAZIN-2-ONE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
  申请人：Sanofi-Aventis

  公开号：EP2310383A1

  公开（公告）日：2011-04-20
• PHARMACEUTICAL COMBINATIONS FOR IMMUNOTHERAPY
  申请人：Technische Universitat Dresden

  公开号：US20170189522A1

  公开（公告）日：2017-07-06

  The present invention relates generally to a method for regulating immune reactions and test substances useful for same. Specifically, the method of the present invention relates to the modulation of the nerve growth factor receptor p75 NTR , which is expressed by plasmacytoid dendritic cells. More specifically, the invention relates to a combination comprising at least one modulator of p75 NTR signalling selected from a p75 NTR antagonist or p75 NTR agonist and at least one TLR receptor agonist selected from an agonist of TLR7 and/or TLR9. The invention further relates to the use of a combination of antagonists and agonists of p75 NTR signalling and agonists of TLR7 and/or TLR9 as vaccine adjuvants and the invention provides vaccine compositions comprising antagonists and agonists of p75 NTR signalling and agonists of TLR7 and/or TLR9. The agonists and antagonists of p75 NTR signalling are useful in the manufacture of drugs for controlling cytokine function, antigen presentation, activation and proliferation of lymphocytes, which is important for the treatment of a range of conditions including cancer, inflammatory conditions, immunological disorders, growth disorders, infections and any other conditions involving p75 NTR signal transduction. The invention provides assays to screen for a range of agonists and antagonists of p75 NTR useful in modulating cytokine function, activation and proliferation of lymphocytes. The present invention further provides, therefore, screening assays for agonists and antagonists of p75NTR-modulated immune responses.
• US8247404B2
  申请人：——

  公开号：US8247404B2

  公开（公告）日：2012-08-21
• [EN] DERIVATIVES OF 2-OXO-ALKYL-1-PIPERAZIN-2-ONE, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME<br/>[FR] DERIVES DE 2-OXO-ALKYL-1-PIPERAZIN-2-ONE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
  申请人：SANOFI AVENTIS

  公开号：WO2009150387A1

  公开（公告）日：2009-12-17

  La présente invention a pour objet des dérivés de dérivés de 4-2-[phényl-3,6- dihydro-pyridin-1 -yl]-2-oxo-alkyl}-1 -pipérazin-2-one et 4-2-[phényl-2,5-dihydro-pyrrol-1 - yl]-2-oxo-alkyl}-1 -pipérazin-2-one de formule générale (I) dans laquelle A, B, m, R3 et n sont définis comme en revendication 1, leur préparation et leur application en thérapeutique.
• [EN] PHARMACEUTICAL COMBINATIONS FOR IMMUNOTHERAPY<br/>[FR] COMBINAISONS PHARMACEUTIQUES DESTINÉES À L'IMMUNOTHÉRAPIE
  申请人：UNIV DRESDEN TECH

  公开号：WO2015181298A1

  公开（公告）日：2015-12-03

  The present invention relates generally to a method for regulating immune reactions and test substances useful for same. Specifically, the method of the present invention relates to the modulation of the nerve growth factor receptor p75NTR, which is expressed by plasmacytoid dendritic cells. More specifically, the invention relates to a combination comprising at least one modulator of p75NTR signalling selected from a p75NTR antagonist or p75NTR agonist and at least one TLR receptor agonist selected from an agonist of TLR7 and/or TLR9. The invention further relates to the use of a combination of antagonists and agonists of p75NTR signalling and agonists of TLR7 and/or TLR9 as vaccine adjuvants and the invention provides vaccine compositions comprising antagonists and agonists of p75NTR signalling and agonists of TLR7 and/or TLR9. The agonists and antagonists of p75NTR signalling are useful in the manufacture of drugs for controlling cytokine function, antigen presentation, activation and proliferation of lymphocytes, which is important for the treatment of a range of conditions including cancer, inflammatory conditions, immunological disorders, growth disorders, infections and any other conditions involving p75NTR signal transduction. The invention provides assays to screen for a range of agonists and antagonists of p75NTR useful in modulating cytokine function, activation and proliferation of lymphocytes. The present invention further provides, therefore, screening assays for agonists and antagonists of p75NTR-modulated immune responses.